UK Rare Disease Clinical Trials Market Size & Outlook
Related Markets
UK rare disease clinical trials market highlights
- The UK rare disease clinical trials market generated a revenue of USD 738.4 million in 2024 and is expected to reach USD 1,127.0 million by 2030.
- The UK market is expected to grow at a CAGR of 7.5% from 2025 to 2030.
- In terms of segment, phase iii was the largest revenue generating phase in 2024.
- Phase I is the most lucrative phase segment registering the fastest growth during the forecast period.
Rare disease clinical trials market data book summary
| Market revenue in 2024 | USD 738.4 million |
| Market revenue in 2030 | USD 1,127.0 million |
| Growth rate | 7.5% (CAGR from 2025 to 2030) |
| Largest segment | Phase iii |
| Fastest growing segment | Phase I |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Other key industry trends
- In terms of revenue, UK accounted for 5.7% of the global rare disease clinical trials market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany rare disease clinical trials market is projected to lead the regional market in terms of revenue in 2030.
- Germany is the fastest growing regional market in Europe and is projected to reach USD 1,191.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Rare Disease Clinical Trials Market Scope
Rare Disease Clinical Trials Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| LabCorp | View profile | - | - | - |
| Parexel International Corporation | View profile | - | - | - |
| Takeda Pharmaceutical Company Limited | View profile | - | - | - |
| F. Hoffmann-La Roche Ltd. | View profile | - | - | - |
| Icon Source | View profile | 11-50 | Denver, Colorado, United States, North America | http://iconsource.com |
| IQVIA | View profile | 10001+ | Danbury, Connecticut, United States, North America | https://www.iqvia.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Charles River Laboratories International Inc | View profile | 21400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | https://www.criver.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
UK rare disease clinical trials market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare disease clinical trials market will help companies and investors design strategic landscapes.
Phase iii was the largest segment with a revenue share of 57.98% in 2024. Horizon Databook has segmented the UK rare disease clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to UK rare disease clinical trials market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of UK rare disease clinical trials market databook
-
Our clientele includes a mix of rare disease clinical trials market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UK rare disease clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into UK rare disease clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
UK rare disease clinical trials market size, by phase, 2018-2030 (US$M)
UK Rare Disease Clinical Trials Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
